Skip to main content
. 2020 Apr 14;11(15):1373–1387. doi: 10.18632/oncotarget.27550

Figure 1. Effect of different Rapatar doses on body weight and PCa tumorigenesis in the psPten –/– mouse model.

Figure 1

Groups were treated with vehicle or either 25 or 5 mg/kg Rapatar (Rapa-25 and Rapa-5 groups, respectively) for 8 weeks. Data for individual animals are shown, with the short horizontal black bar indicating the group mean value. (A) Administration of Rapatar does not affect animal growth. Body weights were measured at the end of the treatment period and plotted as a percentage of initial body weight. (B) Low dose Rapatar treatment reduces prostate tumor burden. The ratio of urogenital tract weight (UG) to body weight (BW) at the end of the experiment is plotted. (C) Low dose Rapatar treatment reduces overall urogenital disease. At the end of the experiment, Disease Index values were calculated as total histologic score*UG weight as described in {Kee, 2004 #123}.